{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["JAK", "binding mode/interactions", "kinase inhibitory activity", "pharmacological uses", "synthesis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35631587", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "05", "Day": "06"}], "Language": ["eng"], "ELocationID": ["1001", "10.3390/pharmaceutics14051001"], "Journal": {"ISSN": "1999-4923", "JournalIssue": {"Volume": "14", "Issue": "5", "PubDate": {"Year": "2022", "Month": "May", "Day": "06"}}, "Title": "Pharmaceutics", "ISOAbbreviation": "Pharmaceutics"}, "ArticleTitle": "A Comprehensive Overview of Globally Approved JAK Inhibitors.", "Abstract": {"AbstractText": ["Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several genes involved in inflammatory, immune, and cancer conditions. Targeting the JAK family kinases with small-molecule inhibitors has proved to be effective in the treatment of different types of diseases. In the current review, eleven of the JAK inhibitors that received approval for clinical use have been discussed. These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. The aim of the current review was to provide an integrated overview of the chemical and pharmacological data of the globally approved JAK inhibitors. The synthetic routes of the eleven drugs were described. In addition, their inhibitory activities against different kinases and their pharmacological uses have also been explained. Moreover, their crystal structures with different kinases were summarized, with a primary focus on their binding modes and interactions. The proposed metabolic pathways and metabolites of these drugs were also illustrated. To sum up, the data in the current review could help in the design of new JAK inhibitors with potential therapeutic benefits in inflammatory and autoimmune diseases."]}, "AuthorList": [{"Identifier": ["0000-0002-3035-661X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Shawky", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0003-4048-1526"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Faisal A", "Initials": "FA"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."}, {"Identifier": [], "Affiliation": "Department of Pharmacy, College of Pharmacy, Riyadh Elm University, Riyadh 11681, Saudi Arabia."}], "LastName": "Abdelazeem", "ForeName": "Ahmed H", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."}], "LastName": "Gouda", "ForeName": "Ahmed M", "Initials": "AM"}], "GrantList": [{"GrantID": "22UQU4331174DSR08", "Agency": "Deanship of Scientific Research at Umm Al-Qura University, KSA", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceutics", "NlmUniqueID": "101534003", "ISSNLinking": "1999-4923"}, "CoiStatement": "Authors declared that there is no conflict of interest and have approved the article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yamaoka K., Saharinen P., Pesu M., Holt V.E.T., 3rd, Silvennoinen O., O\u2019Shea J.J. The Janus kinases (Jaks) Genome Biol. 2004;5:253. doi: 10.1186/gb-2004-5-12-253.", "ArticleIdList": ["10.1186/gb-2004-5-12-253", "PMC545791", "15575979"]}, {"Citation": "Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 1989;86:1603\u20131607. doi: 10.1073/pnas.86.5.1603.", "ArticleIdList": ["10.1073/pnas.86.5.1603", "PMC286746", "2466296"]}, {"Citation": "Banerjee S., Biehl A., Gadina M., Hasni S., Schwartz D.M. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs. 2017;77:521\u2013546. doi: 10.1007/s40265-017-0701-9.", "ArticleIdList": ["10.1007/s40265-017-0701-9", "PMC7102286", "28255960"]}, {"Citation": "Aittom\u00e4ki S., Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin. Pharmacol. Toxicol. 2014;114:18\u201323. doi: 10.1111/bcpt.12164.", "ArticleIdList": ["10.1111/bcpt.12164", "24164900"]}, {"Citation": "Abroun S., Saki N., Ahmadvand M., Asghari F., Salari F., Rahim F. STATs: An old story, yet mesmerizing. Cell J. 2015;17:395\u2013411. doi: 10.22074/cellj.2015.1.", "ArticleIdList": ["10.22074/cellj.2015.1", "PMC4601860", "26464811"]}, {"Citation": "Liau N.P.D., Laktyushin A., Morris R., Sandow J.J., Nicola N.A., Kershaw N.J., Babon J.J. Enzymatic characterization of wild-type and mutant janus kinase 1. Cancers. 2019;11:1701. doi: 10.3390/cancers11111701.", "ArticleIdList": ["10.3390/cancers11111701", "PMC6896158", "31683831"]}, {"Citation": "Min X., Ungureanu D., Maxwell S., Hammar\u00e9n H., Thibault S., Hillert E.-K., Ayres M., Greenfield B., Eksterowicz J., Gabel C., et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2) J. Biol. Chem. 2015;290:27261\u201327270. doi: 10.1074/jbc.M115.672048.", "ArticleIdList": ["10.1074/jbc.M115.672048", "PMC4646372", "26359499"]}, {"Citation": "Garrido-Trigo A., Salas A. Molecular structure and function of Janus kinases: Implications for the development of inhibitors. J. Crohns. Colitis. 2020;14:S713\u2013S724. doi: 10.1093/ecco-jcc/jjz206.", "ArticleIdList": ["10.1093/ecco-jcc/jjz206", "PMC7395311", "32083640"]}, {"Citation": "Ferrao R., Lupardus P.J. The Janus kinase (JAK) FERM and SH2 domains: Bringing specificity to JAK-receptor interactions. Front. Endocrinol. 2017;8:71. doi: 10.3389/fendo.2017.00071.", "ArticleIdList": ["10.3389/fendo.2017.00071", "PMC5394478", "28458652"]}, {"Citation": "Kiu H., Nicholson S.E. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30:88\u2013106. doi: 10.3109/08977194.2012.660936.", "ArticleIdList": ["10.3109/08977194.2012.660936", "PMC3762697", "22339650"]}, {"Citation": "Bryan M.C., Rajapaksa N.S. Kinase inhibitors for the treatment of immunological disorders: Recent advances. J. Med. Chem. 2018;61:9030\u20139058. doi: 10.1021/acs.jmedchem.8b00667.", "ArticleIdList": ["10.1021/acs.jmedchem.8b00667", "29870256"]}, {"Citation": "Xu P., Shen P., Yu B., Xu X., Ge R., Cheng X., Chen Q., Bian J., Li Z., Wang J. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur. J. Med. Chem. 2020;192:112155. doi: 10.1016/j.ejmech.2020.112155.", "ArticleIdList": ["10.1016/j.ejmech.2020.112155", "32120325"]}, {"Citation": "Hammar\u00e9n H.M., Virtanen A.T., Raivola J., Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48\u201363. doi: 10.1016/j.cyto.2018.03.041.", "ArticleIdList": ["10.1016/j.cyto.2018.03.041", "29685781"]}, {"Citation": "Yasuda T., Fukada T., Nishida K., Nakayama M., Matsuda M., Miura I., Dainichi T., Fukuda S., Kabashima K., Nakaoka S., et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J. Clin. Investig. 2016;126:2064\u20132076. doi: 10.1172/JCI82887.", "ArticleIdList": ["10.1172/JCI82887", "PMC4887165", "27111231"]}, {"Citation": "Shen Y., Liu Y., Ke X., Kang H.-Y., Hu G.-H., Hong S.-L. Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis. Asian Pac. J. Allergy Immunol. 2016;34:124\u2013129. doi: 10.12932/AP0630.34.2.2016.", "ArticleIdList": ["10.12932/AP0630.34.2.2016", "27007833"]}, {"Citation": "Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: Central mediator of allergic asthma. Science. 1998;282:2258\u20132261. doi: 10.1126/science.282.5397.2258.", "ArticleIdList": ["10.1126/science.282.5397.2258", "9856949"]}, {"Citation": "Harris C., Cummings J.R.F. JAK1 inhibition and inflammatory bowel disease. Rheumatology. 2021;60:ii45\u2013ii51. doi: 10.1093/rheumatology/keaa896.", "ArticleIdList": ["10.1093/rheumatology/keaa896", "PMC8098109", "33950226"]}, {"Citation": "Virtanen A.T., Haikarainen T., Raivola J., Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33:15\u201332. doi: 10.1007/s40259-019-00333-w.", "ArticleIdList": ["10.1007/s40259-019-00333-w", "PMC6373396", "30701418"]}, {"Citation": "Zak M., Hanan E.J., Lupardus P., Brown D.G., Robinson C., Siu M., Lyssikatos J.P., Romero F.A., Zhao G., Kellar T., et al. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorg. Med. Chem. Lett. 2019;29:1522\u20131531. doi: 10.1016/j.bmcl.2019.04.008.", "ArticleIdList": ["10.1016/j.bmcl.2019.04.008", "30981576"]}, {"Citation": "Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O\u2019Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017;16:843\u2013862. doi: 10.1038/nrd.2017.201.", "ArticleIdList": ["10.1038/nrd.2017.201", "29104284"]}, {"Citation": "Menet C.J. A dual inhibition, a better solution: Development of a JAK1/TYK2 inhibitor. J. Med. Chem. 2018;61:8594\u20138596. doi: 10.1021/acs.jmedchem.8b01397.", "ArticleIdList": ["10.1021/acs.jmedchem.8b01397", "30252456"]}, {"Citation": "Wrobleski S.T., Moslin R., Lin S., Zhang Y., Spergel S., Kempson J., Tokarski J.S., Strnad J., Zupa-Fernandez A., Cheng L., et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165. J. Med. Chem. 2019;62:8973\u20138995. doi: 10.1021/acs.jmedchem.9b00444.", "ArticleIdList": ["10.1021/acs.jmedchem.9b00444", "31318208"]}, {"Citation": "Buchert M., Burns C.J., Ernst M. Targeting JAK kinase in solid tumors: Emerging opportunities and challenges. Oncogene. 2016;35:939\u2013951. doi: 10.1038/onc.2015.150.", "ArticleIdList": ["10.1038/onc.2015.150", "25982279"]}, {"Citation": "Kilpivaara O., Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science. Leukemia. 2008;22:1813\u20131817. doi: 10.1038/leu.2008.229.", "ArticleIdList": ["10.1038/leu.2008.229", "18754026"]}, {"Citation": "Treli\u0144ski J., Robak T. JAK inhibitors: Pharmacology and clinical activity in chronic myeloprolipherative neoplasms. Curr. Med. Chem. 2013;20:1147\u20131161. doi: 10.2174/0929867311320090004.", "ArticleIdList": ["10.2174/0929867311320090004", "23317159"]}, {"Citation": "Nielsen C., Birgens H.S., Nordestgaard B.G., Kjaer L., Bojesen S.E. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96:450\u2013453. doi: 10.3324/haematol.2010.033191.", "ArticleIdList": ["10.3324/haematol.2010.033191", "PMC3046277", "21160067"]}, {"Citation": "Leroy E., Constantinescu S.N. Rethinking JAK2 inhibition: Towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017;31:1023\u20131038. doi: 10.1038/leu.2017.43.", "ArticleIdList": ["10.1038/leu.2017.43", "28119526"]}, {"Citation": "Mascarenhas J., Hoffman R. Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012;18:3008\u20133014. doi: 10.1158/1078-0432.CCR-11-3145.", "ArticleIdList": ["10.1158/1078-0432.CCR-11-3145", "22474318"]}, {"Citation": "Raedler L.A. Jakafi (Ruxolitinib): First FDA-approved medication for the treatment of patients with polycythemia vera. Am. Health Drug Benefits. 2015;8:75\u201379.", "ArticleIdList": ["PMC4665047", "26629270"]}, {"Citation": "Hart S., Goh K.C., Novotny-Diermayr V., Tan Y.C., Madan B., Amalini C., Ong L.C., Kheng B., Cheong A., Zhou J., et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011;1:e44. doi: 10.1038/bcj.2011.43.", "ArticleIdList": ["10.1038/bcj.2011.43", "PMC3256753", "22829080"]}, {"Citation": "Yang T., Hu M., Qi W., Yang Z., Tang M., He J., Chen Y., Bai P., Yuan X., Zhang C., et al. Discovery of potent and orally effective dual Janus kinase 2/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms. J. Med. Chem. 2019;62:10305\u201310320. doi: 10.1021/acs.jmedchem.9b01348.", "ArticleIdList": ["10.1021/acs.jmedchem.9b01348", "31670517"]}, {"Citation": "Hu X., Li J., Fu M., Zhao X., Wang W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct. Target. Ther. 2021;6:402. doi: 10.1038/s41392-021-00791-1.", "ArticleIdList": ["10.1038/s41392-021-00791-1", "PMC8617206", "34824210"]}, {"Citation": "Angelini J., Talotta R., Roncato R., Fornasier G., Barbiero G., Dal Cin L., Brancati S., Scaglione F. JAK-Inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules. 2020;10:1002. doi: 10.3390/biom10071002.", "ArticleIdList": ["10.3390/biom10071002", "PMC7408575", "32635659"]}, {"Citation": "Vainchenker W., Leroy E., Gilles L., Marty C., Plo I., Constantinescu S.N. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research. 2018;7:82. doi: 10.12688/f1000research.13167.1.", "ArticleIdList": ["10.12688/f1000research.13167.1", "PMC5773931", "29399328"]}, {"Citation": "Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13:311\u2013320. doi: 10.1016/j.ccr.2008.02.009.", "ArticleIdList": ["10.1016/j.ccr.2008.02.009", "18394554"]}, {"Citation": "Singh D., Bogus M., Moskalenko V., Lord R., Moran E.J., Crater G.D., Bourdet D.L., Pfeifer N.D., Woo J., Kaufman E., et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. Eur. Respir. J. 2021;58:2100673. doi: 10.1183/13993003.00673-2021.", "ArticleIdList": ["10.1183/13993003.00673-2021", "PMC8859971", "34210790"]}, {"Citation": "Andraos R., Qian Z., Bonenfant D., Rubert J., Vangrevelinghe E., Scheufler C., Marque F., R\u00e9gnier C.H., De Pover A., Ryckelynck H., et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012;2:512\u2013523. doi: 10.1158/2159-8290.CD-11-0324.", "ArticleIdList": ["10.1158/2159-8290.CD-11-0324", "PMC5022112", "22684457"]}, {"Citation": "Wu S.-C., Li L.S., Kopp N., Montero J., Chapuy B., Yoda A., Christie A.L., Liu H., Christodoulou A., van Bodegom D., et al. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell. 2015;28:29\u201341. doi: 10.1016/j.ccell.2015.06.005.", "ArticleIdList": ["10.1016/j.ccell.2015.06.005", "PMC4505625", "26175414"]}, {"Citation": "Burke J.R., Cheng L., Gillooly K.M., Strnad J., Zupa-Fernandez A., Catlett I.M., Zhang Y., Heimrich E.M., McIntyre K.W., Cunningham M.D., et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci. Transl. Med. 2019;11:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.", "ArticleIdList": ["10.1126/scitranslmed.aaw1736", "31341059"]}, {"Citation": "Lipka D.B., Hoffmann L.S., Heidel F., Markova B., Blum M.-C., Breitenbuecher F., Kasper S., Kindler T., Levine R.L., Huber C., et al. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol. Cancer Ther. 2008;7:1176\u20131184. doi: 10.1158/1535-7163.MCT-07-2215.", "ArticleIdList": ["10.1158/1535-7163.MCT-07-2215", "18483305"]}, {"Citation": "Jatiani S.S., Cosenza S.C., Reddy M.V.R., Ha J.H., Baker S.J., Samanta A.K., Olnes M.J., Pfannes L., Sloand E.M., Arlinghaus R.B., et al. A non-ATP-competitive dual inhibitor of JAK2 and BCR-ABL kinases: Elucidation of a novel therapeutic spectrum based on substrate competitive inhibition. Genes Cancer. 2010;1:331\u2013345. doi: 10.1177/1947601910371337.", "ArticleIdList": ["10.1177/1947601910371337", "PMC2921666", "20717479"]}, {"Citation": "Alexander M., Luo Y., Raimondi G., O\u2019Shea J.J., Gadina M. Jakinibs of all trades: Inhibiting cytokine signaling in immune-mediated pathologies. Pharmaceuticals. 2022;15:48. doi: 10.3390/ph15010048.", "ArticleIdList": ["10.3390/ph15010048", "PMC8779366", "35056105"]}, {"Citation": "Casimiro-Garcia A., Trujillo J.I., Vajdos F., Juba B., Banker M.E., Aulabaugh A., Balbo P., Bauman J., Chrencik J., Coe J.W., et al. Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors. J. Med. Chem. 2018;61:10665\u201310699. doi: 10.1021/acs.jmedchem.8b01308.", "ArticleIdList": ["10.1021/acs.jmedchem.8b01308", "30423248"]}, {"Citation": "Goedken E.R., Argiriadi M.A., Banach D.L., Fiamengo B.A., Foley S.E., Frank K.E., George J.S., Harris C.M., Hobson A.D., Ihle D.C., et al. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J. Biol. Chem. 2015;290:4573\u20134589. doi: 10.1074/jbc.M114.595181.", "ArticleIdList": ["10.1074/jbc.M114.595181", "PMC4335200", "25552479"]}, {"Citation": "Forster M., Chaikuad A., Bauer S.M., Holstein J., Robers M.B., Corona C.R., Gehringer M., Pfaffenrot E., Ghoreschi K., Knapp S., et al. Selective JAK3 Inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem. Biol. 2016;23:1335\u20131340. doi: 10.1016/j.chembiol.2016.10.008.", "ArticleIdList": ["10.1016/j.chembiol.2016.10.008", "PMC5119931", "27840070"]}, {"Citation": "Telliez J.-B., Dowty M.E., Wang L., Jussif J., Lin T., Li L., Moy E., Balbo P., Li W., Zhao Y., et al. Discovery of a JAK3-selective inhibitor: Functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem. Biol. 2016;11:3442\u20133451. doi: 10.1021/acschembio.6b00677.", "ArticleIdList": ["10.1021/acschembio.6b00677", "27791347"]}, {"Citation": "Dassault Systems BIOVIA . Discovery Studio Visualizer. Dassault Systems; San Diego, CA, USA: 2016. version 16.1.0.15350."}, {"Citation": "Almalki F.A., Shawky A.M., Abdalla A.N., Gouda A.M. Icotinib, almonertinib, and olmutinib: A 2D similarity/docking-based study to predict the potential binding modes and interactions into EGFR. Molecules. 2021;26:6423. doi: 10.3390/molecules26216423.", "ArticleIdList": ["10.3390/molecules26216423", "PMC8588130", "34770832"]}, {"Citation": "Abourehab M.A.S., Alqahtani A.M., Almalki F.A., Zaher D.M., Abdalla A.N., Gouda A.M., Beshr E.A.M. Pyrrolizine/indolizine-NSAID hybrids: Design, synthesis, biological evaluation, and molecular docking studies. Molecules. 2021;26:6582. doi: 10.3390/molecules26216582.", "ArticleIdList": ["10.3390/molecules26216582", "PMC8588198", "34770990"]}, {"Citation": "Abourehab M.A.S., Alqahtani A.M., Youssif B.G.M., Gouda A.M. Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules. 2021;26:6677. doi: 10.3390/molecules26216677.", "ArticleIdList": ["10.3390/molecules26216677", "PMC8587155", "34771085"]}, {"Citation": "Arulogun S.O., Choong H.-L., Taylor D., Ambrosoli P., Magor G., Irving I.M., Keng T.-B., Perkins A.C. JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica. 2017;102:e324\u2013e327. doi: 10.3324/haematol.2017.170266.", "ArticleIdList": ["10.3324/haematol.2017.170266", "PMC5541888", "28550193"]}, {"Citation": "Musumeci F., Greco C., Giacchello I., Fallacara A.L., Ibrahim M.M., Grossi G., Brullo C., Schenone S. An update on JAK inhibitors. Curr. Med. Chem. 2019;26:1806\u20131832. doi: 10.2174/0929867325666180327093502.", "ArticleIdList": ["10.2174/0929867325666180327093502", "29589523"]}, {"Citation": "Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer. 2007;7:673\u2013683. doi: 10.1038/nrc2210.", "ArticleIdList": ["10.1038/nrc2210", "17721432"]}, {"Citation": "Degryse S., Bornschein S., de Bock C.E., Leroy E., Vanden Bempt M., Demeyer S., Jacobs K., Geerdens E., Gielen O., Soulier J., et al. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood. 2018;131:421\u2013425. doi: 10.1182/blood-2017-07-797597.", "ArticleIdList": ["10.1182/blood-2017-07-797597", "PMC5796683", "29187379"]}, {"Citation": "O\u2019Shea J.J., Husa M., Li D., Hofmann S.R., Watford W., Roberts J.L., Buckley R.H., Changelian P., Candotti F. JAK3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. 2004;41:727\u2013737. doi: 10.1016/j.molimm.2004.04.014.", "ArticleIdList": ["10.1016/j.molimm.2004.04.014", "15220007"]}, {"Citation": "Nemoto M., Hattori H., Maeda N., Akita N., Muramatsu H., Moritani S., Kawasaki T., Maejima M., Ode H., Hachiya A., et al. Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia. Sci. Rep. 2018;8:6956. doi: 10.1038/s41598-018-25260-8.", "ArticleIdList": ["10.1038/s41598-018-25260-8", "PMC5934390", "29725107"]}, {"Citation": "Wu P., Chen S., Wu B., Chen J., Lv G. A TYK2 gene mutation c.2395G>A leads to TYK2 deficiency: A case report and literature review. Front. Pediatr. 2020;8:253. doi: 10.3389/fped.2020.00253.", "ArticleIdList": ["10.3389/fped.2020.00253", "PMC7267021", "32537443"]}, {"Citation": "Menet C.J., van Rompaey L., Geney R. Advances in the discovery of selective JAK inhibitors. Prog. Med. Chem. 2013;52:153\u2013223. doi: 10.1016/B978-0-444-62652-3.00004-1.", "ArticleIdList": ["10.1016/B978-0-444-62652-3.00004-1", "23384668"]}, {"Citation": "Vazquez M.L., Kaila N., Strohbach J.W., Trzupek J.D., Brown M.F., Flanagan M.E., Mitton-Fry M.J., Johnson T.A., TenBrink R.E., Arnold E.P., et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. J. Med. Chem. 2018;61:1130\u20131152. doi: 10.1021/acs.jmedchem.7b01598.", "ArticleIdList": ["10.1021/acs.jmedchem.7b01598", "29298069"]}, {"Citation": "Lucet I.S., Fantino E., Styles M., Bamert R., Patel O., Broughton S.E., Walter M., Burns C.J., Treutlein H., Wilks A.F., et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107:176\u2013183. doi: 10.1182/blood-2005-06-2413.", "ArticleIdList": ["10.1182/blood-2005-06-2413", "16174768"]}, {"Citation": "Thoma G., Nuninger F., Falchetto R., Hermes E., Tavares G.A., Vangrevelinghe E., Zerwes H.-G. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J. Med. Chem. 2011;54:284\u2013288. doi: 10.1021/jm101157q.", "ArticleIdList": ["10.1021/jm101157q", "21155605"]}, {"Citation": "Fensome A., Ambler C.M., Arnold E., Banker M.E., Clark J.D., Dowty M.E., Efremov I.V., Flick A., Gerstenberger B.S., Gifford R.S., et al. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. Bioorg. Med. Chem. 2020;28:115481. doi: 10.1016/j.bmc.2020.115481.", "ArticleIdList": ["10.1016/j.bmc.2020.115481", "32253095"]}, {"Citation": "Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., et al. Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature. 1996;379:645\u2013648. doi: 10.1038/379645a0.", "ArticleIdList": ["10.1038/379645a0", "8628398"]}, {"Citation": "Coricello A., Mesiti F., Lupia A., Maruca A., Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates. Molecules. 2020;25:3321. doi: 10.3390/molecules25153321.", "ArticleIdList": ["10.3390/molecules25153321", "PMC7435994", "32707925"]}, {"Citation": "Markham A. Baricitinib: First global approval. Drugs. 2017;77:697\u2013704. doi: 10.1007/s40265-017-0723-3.", "ArticleIdList": ["10.1007/s40265-017-0723-3", "28290136"]}, {"Citation": "Blair H.A. Fedratinib: First approval. Drugs. 2019;79:1719\u20131725. doi: 10.1007/s40265-019-01205-x.", "ArticleIdList": ["10.1007/s40265-019-01205-x", "31571162"]}, {"Citation": "Duggan S., Keam S.J. Upadacitinib: First approval. Drugs. 2019;79:1819\u20131828. doi: 10.1007/s40265-019-01211-z.", "ArticleIdList": ["10.1007/s40265-019-01211-z", "31642025"]}, {"Citation": "Markham A., Keam S.J. Peficitinib: First global approval. Drugs. 2019;79:887\u2013891. doi: 10.1007/s40265-019-01131-y.", "ArticleIdList": ["10.1007/s40265-019-01131-y", "31093950"]}, {"Citation": "Dhillon S. Delgocitinib: First approval. Drugs. 2020;80:609\u2013615. doi: 10.1007/s40265-020-01291-2.", "ArticleIdList": ["10.1007/s40265-020-01291-2", "32166597"]}, {"Citation": "Dhillon S., Keam S.J. Filgotinib: First approval. Drugs. 2020;80:1987\u20131997. doi: 10.1007/s40265-020-01439-0.", "ArticleIdList": ["10.1007/s40265-020-01439-0", "PMC7858213", "33237566"]}, {"Citation": "Connor C.G., DeForest J.C., Dietrich P., Do N.M., Doyle K.M., Eisenbeis S., Greenberg E., Griffin S.H., Jones B.P., Jones K.N., et al. Development of a nitrene-type rearrangement for the commercial route of the JAK1 inhibitor abrocitinib. Org. Process Res. Dev. 2021;25:608\u2013615. doi: 10.1021/acs.oprd.0c00366.", "ArticleIdList": ["10.1021/acs.oprd.0c00366"]}, {"Citation": "Deeks E.D., Duggan S. Abrocitinib: First approval. Drugs. 2021;81:2149\u20132157. doi: 10.1007/s40265-021-01638-3.", "ArticleIdList": ["10.1007/s40265-021-01638-3", "PMC8917037", "34807428"]}, {"Citation": "Eichenfield L.F., Flohr C., Sidbury R., Siegfried E., Szalai Z., Galus R., Yao Z., Takahashi H., Barbarot S., Feeney C., et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157:1165\u20131173. doi: 10.1001/jamadermatol.2021.2830.", "ArticleIdList": ["10.1001/jamadermatol.2021.2830", "PMC8374743", "34406366"]}, {"Citation": "Bieber T., Simpson E.L., Silverberg J.I., Tha\u00e7i D., Paul C., Pink A.E., Kataoka Y., Chu C.-Y., DiBonaventura M., Rojo R., et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N. Engl. J. Med. 2021;384:1101\u20131112. doi: 10.1056/NEJMoa2019380.", "ArticleIdList": ["10.1056/NEJMoa2019380", "33761207"]}, {"Citation": "Blauvelt A., Silverberg J.I., Lynde C.W., Bieber T., Eisman S., Zdybski J., Gubelin W., Simpson E.L., Valenzuela F., Criado P.R., et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J. Am. Acad. Dermatol. 2022;86:104\u2013112. doi: 10.1016/j.jaad.2021.05.075.", "ArticleIdList": ["10.1016/j.jaad.2021.05.075", "34416294"]}, {"Citation": "Wang E.Q., Le V., O\u2019Gorman M., Tripathy S., Dowty M.E., Wang L., Malhotra B.K. Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites. J. Clin. Pharmacol. 2021;61:1311\u20131323. doi: 10.1002/jcph.1858.", "ArticleIdList": ["10.1002/jcph.1858", "PMC8518898", "33749838"]}, {"Citation": "European Medicines Agency EMA/MB/69923/2010, Abrocitinib Assessment Report.  [(accessed on 14 February 2022)].  Available online:  https://www.ema.europa.eu/en/documents/assessment-report/cibinqo-epar-public-assessment-report_en.pdf."}, {"Citation": "FDA Fact Sheet for Healthcare Providers Emergency use Authorization (EUA) of Baricitinib.  [(accessed on 20 April 2022)]; Available online:  https://www.fda.gov/media/143823/download."}, {"Citation": "Rodgers J.D., Shepard S. Azetidine and Cyclobutane Derivatives as JAK Inhibitors. 8,158,616. US Patent. 2012 April 17;"}, {"Citation": "Xu J., Cai J., Chen J., Zong X., Wu X., Ji M., Wang P. An efficient synthesis of baricitinib. J. Chem. Res. 2016;40:205\u2013208. doi: 10.3184/174751916X14569294811333.", "ArticleIdList": ["10.3184/174751916X14569294811333"]}, {"Citation": "Azad M.A.K., Pandey G., Singh K., Prasad M. Process for the Preparation of Baricitinib and an Intermediate Thereof. US10526350B2. U.S. Patent. 2020 January 7;"}, {"Citation": "Cui X., Du J., Jia Z., Wang X., Jia H. A green and facile synthesis of an industrially important quaternary heterocyclic intermediates for baricitinib. BMC Chem. 2019;13:123. doi: 10.1186/s13065-019-0639-y.", "ArticleIdList": ["10.1186/s13065-019-0639-y", "PMC6824028", "31696160"]}, {"Citation": "Clark J.D., Flanagan M.E., Telliez J.-B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J. Med. Chem. 2014;57:5023\u20135038. doi: 10.1021/jm401490p.", "ArticleIdList": ["10.1021/jm401490p", "24417533"]}, {"Citation": "Sorrell F.J., Szklarz M., Abdul Azeez K.R., Elkins J.M., Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24:401\u2013411. doi: 10.1016/j.str.2015.12.015.", "ArticleIdList": ["10.1016/j.str.2015.12.015", "PMC4780864", "26853940"]}, {"Citation": "Davis R.R., Li B., Yun S.Y., Chan A., Nareddy P., Gunawan S., Ayaz M., Lawrence H.R., Reuther G.W., Lawrence N.J., et al. Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof. J. Med. Chem. 2021;64:2228\u20132241. doi: 10.1021/acs.jmedchem.0c01952.", "ArticleIdList": ["10.1021/acs.jmedchem.0c01952", "PMC8327781", "33570945"]}, {"Citation": "Chang Y., Min J., Jarusiewicz J., Actis M., Bradford S.Y.-C., Mayasundari A., Yang L., Chepyala D., Alcock L.J., Roberts K.G., et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021;138:2313\u20132326. doi: 10.1182/blood.2020006846.", "ArticleIdList": ["10.1182/blood.2020006846", "PMC8662068", "34110416"]}, {"Citation": "Wan M., Cao X. BMP signaling in skeletal development. Biochem. Biophys. Res. Commun. 2005;328:651\u2013657. doi: 10.1016/j.bbrc.2004.11.067.", "ArticleIdList": ["10.1016/j.bbrc.2004.11.067", "15694398"]}, {"Citation": "Al-Salama Z.T., Scott L.J. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018;78:761\u2013772. doi: 10.1007/s40265-018-0908-4.", "ArticleIdList": ["10.1007/s40265-018-0908-4", "29687421"]}, {"Citation": "Wallace D.J., Furie R.A., Tanaka Y., Kalunian K.C., Mosca M., Petri M.A., D\u00f6rner T., Cardiel M.H., Bruce I.N., Gomez E., et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222\u2013231. doi: 10.1016/S0140-6736(18)31363-1.", "ArticleIdList": ["10.1016/S0140-6736(18)31363-1", "30043749"]}, {"Citation": "Guttman-Yassky E., Silverberg J.I., Nemoto O., Forman S.B., Wilke A., Prescilla R., de la Pe\u00f1a A., Nunes F.P., Janes J., Gamalo M., et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J. Am. Acad. Dermatol. 2019;80:913\u2013921.e9. doi: 10.1016/j.jaad.2018.01.018.", "ArticleIdList": ["10.1016/j.jaad.2018.01.018", "29410014"]}, {"Citation": "Hasan M.J., Rabbani R., Anam A.M., Huq S.M.R. Additional baricitinib loading dose improves clinical outcome in COVID-19. Open Med. 2021;16:41\u201346. doi: 10.1515/med-2021-0010.", "ArticleIdList": ["10.1515/med-2021-0010", "PMC7729634", "33364433"]}, {"Citation": "Kalil A.C., Patterson T.F., Mehta A.K., Tomashek K.M., Wolfe C.R., Ghazaryan V., Marconi V.C., Ruiz-Palacios G.M., Hsieh L., Kline S., et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med. 2020;384:795\u2013807. doi: 10.1056/NEJMoa2031994.", "ArticleIdList": ["10.1056/NEJMoa2031994", "PMC7745180", "33306283"]}, {"Citation": "Izumo T., Kuse N., Awano N., Tone M., Sakamoto K., Takada K., Muto Y., Fujimoto K., Saiki A., Ito Y., et al. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. Respir. Investig. 2021;59:799\u2013803. doi: 10.1016/j.resinv.2021.07.004.", "ArticleIdList": ["10.1016/j.resinv.2021.07.004", "PMC8352677", "34413006"]}, {"Citation": "Eli Lilly & Co. Baricitinib  U.S. Food and Drug Administration Website.  [(accessed on 16 February 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000PharmR.pdf."}, {"Citation": "Eli Lilly Australia Pty Ltd.  Olumiant Australian Public Assessment Report for Baricitinib.  [(accessed on 16 February 2022)]; Available online:  https://www.tga.gov.au/sites/default/files/auspar-baricitinib-190321.pdf."}, {"Citation": "Noji S., Hara Y., Miura T., Yamanaka H., Maeda K., Hori A., Yamamoto H., Obika S., Inoue M., Hase Y., et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders. J. Med. Chem. 2020;63:7163\u20137185. doi: 10.1021/acs.jmedchem.0c00450.", "ArticleIdList": ["10.1021/acs.jmedchem.0c00450", "32511913"]}, {"Citation": "Takiguchi H., Higashi A., Watanabe T., Takeichi T., Shimazaki T., Inaba T. Stereocontrolled synthesis of delgocitinib, a JAK inhibitor for the treatment of atopic dermatitis. Org. Process Res. Dev. 2021;25:342\u2013348. doi: 10.1021/acs.oprd.1c00031.", "ArticleIdList": ["10.1021/acs.oprd.1c00031"]}, {"Citation": "Nakagawa H., Nemoto O., Igarashi A., Saeki H., Kaino H., Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J. Am. Acad. Dermatol. 2020;82:823\u2013831. doi: 10.1016/j.jaad.2019.12.015.", "ArticleIdList": ["10.1016/j.jaad.2019.12.015", "32029304"]}, {"Citation": "Tanimoto A., Ogawa Y., Oki C., Kimoto Y., Nozawa K., Amano W., Noji S., Shiozaki M., Matsuo A., Shinozaki Y., et al. Pharmacological properties of JTE-052: A novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm. Res. 2015;64:41\u201351. doi: 10.1007/s00011-014-0782-9.", "ArticleIdList": ["10.1007/s00011-014-0782-9", "PMC4286029", "25387665"]}, {"Citation": "Worm M., Bauer A., Elsner P., Mahler V., Molin S., Nielsen T.S.S. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: Data from a randomized, double-blind, vehicle-controlled phase IIa study. Br. J. Dermatol. 2020;182:1103\u20131110. doi: 10.1111/bjd.18469.", "ArticleIdList": ["10.1111/bjd.18469", "31466119"]}, {"Citation": "Xie Z., Yang X., Duan Y., Han J., Liao C. Small-molecule kinase inhibitors for the treatment of nononcologic diseases. J. Med. Chem. 2021;64:1283\u20131345. doi: 10.1021/acs.jmedchem.0c01511.", "ArticleIdList": ["10.1021/acs.jmedchem.0c01511", "33481605"]}, {"Citation": "Nakagawa H., Nemoto O., Yamada H., Nagata T., Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J. Dermatol. 2018;45:701\u2013709. doi: 10.1111/1346-8138.14322.", "ArticleIdList": ["10.1111/1346-8138.14322", "PMC6001687", "29665062"]}, {"Citation": "Japan Tobacco Inc.  Report on the Deliberation Results, Corectim Ointment 0.5% (Delgocitinib)  [(accessed on 16 February 2022)].  Available online:  https://www.pmda.go.jp/files/000240793.pdf."}, {"Citation": "Flick A.C., Leverett C.A., Ding H.X., McInturff E., Fink S.J., Mahapatra S., Carney D.W., Lindsey E.A., DeForest J.C., France S.P., et al. Synthetic approaches to the new drugs approved during 2019. J. Med. Chem. 2021;64:3604\u20133657. doi: 10.1021/acs.jmedchem.1c00208.", "ArticleIdList": ["10.1021/acs.jmedchem.1c00208", "33783211"]}, {"Citation": "Wang Y., Li H. Diphenylaminopyrimidine Compound for Inhibiting Kinase Activity. US20200071303A1. U.S. Patent. 2020 March 5;"}, {"Citation": "Noronha G., Mak C.C., Cao J., Renick J., McPherson A., Zeng B., Pathak V.P., Lohse D.L., Hood J.D., Soll R.M. Preparation of Pyrimidine Derivatives as JAK Kinases Inhibitors. US20110212077A1. U.S. Patent. 2011 September 1;"}, {"Citation": "Tefferi A. N-tert-Butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1- ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide for treating myelofibrosis. WO2012060847A1. 2012 May 10;"}, {"Citation": "Ciceri P., M\u00fcller S., O\u2019Mahony A., Fedorov O., Filippakopoulos P., Hunt J.P., Lasater E.A., Pallares G., Picaud S., Wells C., et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 2014;10:305\u2013312. doi: 10.1038/nchembio.1471.", "ArticleIdList": ["10.1038/nchembio.1471", "PMC3998711", "24584101"]}, {"Citation": "Ember S.W.J., Zhu J.-Y., Olesen S.H., Martin M.P., Becker A., Berndt N., Georg G.I., Sch\u00f6nbrunn E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 2014;9:1160\u20131171. doi: 10.1021/cb500072z.", "ArticleIdList": ["10.1021/cb500072z", "PMC4032195", "24568369"]}, {"Citation": "Talpaz M., Kiladjian J.-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021;35:1\u201317. doi: 10.1038/s41375-020-0954-2.", "ArticleIdList": ["10.1038/s41375-020-0954-2", "PMC7787977", "32647323"]}, {"Citation": "Poubel C.P., Mansur M.B., Boroni M., Emerenciano M. FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms. Biochim. Biophys. Acta Rev. Cancer. 2019;1872:80\u201388. doi: 10.1016/j.bbcan.2019.06.001.", "ArticleIdList": ["10.1016/j.bbcan.2019.06.001", "31201827"]}, {"Citation": "Muller S., Filippakopoulos P., Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 2011;13:e29. doi: 10.1017/S1462399411001992.", "ArticleIdList": ["10.1017/S1462399411001992", "PMC3177561", "21933453"]}, {"Citation": "Ogasawara K., Xu C., Kanamaluru V., Siebers N., Surapaneni S., Ridoux L., Palmisano M., Krishna G. Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects. Cancer Chemother. Pharmacol. 2020;86:307\u2013314. doi: 10.1007/s00280-020-04121-0.", "ArticleIdList": ["10.1007/s00280-020-04121-0", "32748109"]}, {"Citation": "Menet C.J.M., van Rompaey L.J.C., Robert S., Blanc J., Jouannigot N., Hodges A.J., Smits K.K. Novel Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases. WO2010010190A1. 2021 January 28;"}, {"Citation": "Ayala-Aguilera C.C., Valero T., Lorente-Mac\u00edas \u00c1., Baillache D.J., Croke S., Unciti-Broceta A. Small molecule kinase inhibitor drugs (1995\u20132021): Medical indication, pharmacology, and synthesis. J. Med. Chem. 2021;65:1047\u20131131. doi: 10.1021/acs.jmedchem.1c00963.", "ArticleIdList": ["10.1021/acs.jmedchem.1c00963", "34624192"]}, {"Citation": "Van Rompaey L., Galien R., van der Aar E.M., Clement-Lacroix P., Nelles L., Smets B., Lepescheux L., Christophe T., Conrath K., Vandeghinste N., et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol. 2013;191:3568\u20133577. doi: 10.4049/jimmunol.1201348.", "ArticleIdList": ["10.4049/jimmunol.1201348", "24006460"]}, {"Citation": "Menet C.J., Fletcher S.R., Van Lommen G., Geney R., Blanc J., Smits K., Jouannigot N., Deprez P., van der Aar E.M., Clement-Lacroix P., et al. Triazolopyridines as selective JAK1 inhibitors: From hit identification to GLPG0634. J. Med. Chem. 2014;57:9323\u20139342. doi: 10.1021/jm501262q.", "ArticleIdList": ["10.1021/jm501262q", "25369270"]}, {"Citation": "Newton A.S., Deiana L., Puleo D.E., Cisneros J.A., Cutrona K.J., Schlessinger J., Jorgensen W.L. JAK2 JH2 Fluorescence polarization assay and crystal structures for complexes with three small molecules. ACS Med. Chem. Lett. 2017;8:614\u2013617. doi: 10.1021/acsmedchemlett.7b00154.", "ArticleIdList": ["10.1021/acsmedchemlett.7b00154", "PMC5467202", "28626520"]}, {"Citation": "Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs. 2014;23:1067\u20131077. doi: 10.1517/13543784.2014.918604.", "ArticleIdList": ["10.1517/13543784.2014.918604", "24818516"]}, {"Citation": "Vanhoutte F., Mazur M., Voloshyn O., Stanislavchuk M., Van der Aa A., Namour F., Galien R., Meuleners L., van \u2019t Klooster G. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: Results of two randomized phase IIa trials. Arthritis Rheumatol. 2017;69:1949\u20131959. doi: 10.1002/art.40186.", "ArticleIdList": ["10.1002/art.40186", "PMC5656813", "28622463"]}, {"Citation": "Westhovens R., Taylor P.C., Alten R., Pavlova D., Enr\u00edquez-Sosa F., Mazur M., Greenwald M., Van der Aa A., Vanhoutte F., Tasset C., et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1) Ann. Rheum. Dis. 2017;76:998\u20131008. doi: 10.1136/annrheumdis-2016-210104.", "ArticleIdList": ["10.1136/annrheumdis-2016-210104", "27993829"]}, {"Citation": "Labetoulle R., Paul S., Roblin X. Filgotinib for the treatment of Crohn\u2019s disease. Expert Opin. Investig. Drugs. 2018;27:295\u2013300. doi: 10.1080/13543784.2018.1442433.", "ArticleIdList": ["10.1080/13543784.2018.1442433", "29448862"]}, {"Citation": "Vermeire S., Schreiber S., Petryka R., Kuehbacher T., Hebuterne X., Roblin X., Klopocka M., Goldis A., Wisniewska-Jarosinska M., Baranovsky A., et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266\u2013275. doi: 10.1016/S0140-6736(16)32537-5.", "ArticleIdList": ["10.1016/S0140-6736(16)32537-5", "27988142"]}, {"Citation": "Feagan B.G., Danese S., Loftus E.V.J., Vermeire S., Schreiber S., Ritter T., Fogel R., Mehta R., Nijhawan S., Kempi\u0144ski R., et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u20132384. doi: 10.1016/S0140-6736(21)00666-8.", "ArticleIdList": ["10.1016/S0140-6736(21)00666-8", "34090625"]}, {"Citation": "Mease P., Coates L.C., Helliwell P.S., Stanislavchuk M., Rychlewska-Hanczewska A., Dudek A., Abi-Saab W., Tasset C., Meuleners L., Harrison P., et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2367\u20132377. doi: 10.1016/S0140-6736(18)32483-8.", "ArticleIdList": ["10.1016/S0140-6736(18)32483-8", "30360969"]}, {"Citation": "Namour F., Diderichsen P.M., Cox E., Vayssi\u00e8re B., Van der Aa A., Tasset C., Van\u2019t Klooster G. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin. Pharmacokinet. 2015;54:859\u2013874. doi: 10.1007/s40262-015-0240-z.", "ArticleIdList": ["10.1007/s40262-015-0240-z", "PMC4513223", "25681059"]}, {"Citation": "Van\u2019t Klooster G.A.E., Brys R.C.X., Van Rompaey L.J.C., Namour F.S. Aminotriazolopyridine for Use in the Treatment of Inflammation, and Pharmaceutical Compositions Thereof. WO2013189771A1. 2013 December 27;"}, {"Citation": "Namour F., Desrivot J., Van der Aa A., Harrison P., Tasset C., van\u2019t Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab. Lett. 2016;10:38\u201348. doi: 10.2174/1872312810666151223103353.", "ArticleIdList": ["10.2174/1872312810666151223103353", "26693854"]}, {"Citation": "Gonzales A.J., Bowman J.W., Fici G.J., Zhang M., Mann D.W., Mitton-Fry M. Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther. 2014;37:317\u2013324. doi: 10.1111/jvp.12101.", "ArticleIdList": ["10.1111/jvp.12101", "PMC4265276", "24495176"]}, {"Citation": "Berlinski P.J., Birchmeier M.J., Bowman J.W., Gonzales A.J., Kamerling S.G., Mann D.W., Mitton-Fry M.J. Pyrrolo[2,3-d]Pyrimidine Compounds. WO2010020905A1. 2010 February 25;"}, {"Citation": "Haugh I.M., Watson I.T., Alan Menter M. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib. Bayl. Univ. Med. Cent. Proc. 2018;31:524\u2013525. doi: 10.1080/08998280.2018.1480246.", "ArticleIdList": ["10.1080/08998280.2018.1480246", "PMC6413965", "30949000"]}, {"Citation": "Cosgrove S.B., Wren J.A., Cleaver D.M., Martin D.D., Walsh K.F., Harfst J.A., Follis S.L., King V.L., Boucher J.F., Stegemann M.R. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet. Dermatol. 2013;24:479-e114. doi: 10.1111/vde.12047.", "ArticleIdList": ["10.1111/vde.12047", "PMC4282347", "23829933"]}, {"Citation": "Rynhoud H., Gibson J.S., Meler E., Soares Magalh\u00e3es R.J. The association between the use of oclacitinib and antibacterial therapy in dogs with allergic dermatitis: A retrospective case-control study. Front. Vet. Sci. 2021;8:631443. doi: 10.3389/fvets.2021.631443.", "ArticleIdList": ["10.3389/fvets.2021.631443", "PMC7928369", "33681331"]}, {"Citation": "Banovic F., Tarigo J., Gordon H., Barber J.P., Gogal R.M.J. Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production. Vet. Dermatol. 2019;30:17-e6. doi: 10.1111/vde.12698.", "ArticleIdList": ["10.1111/vde.12698", "30417482"]}, {"Citation": "De Caro Martins G., da Costa-Val A.P., Coura F.M., Diamantino G.M.L., Nogueira M.M., de Oliveira Melo-Junior O.A., Giunchetti R.C., da Silveira-Lemos D., Melo M.M. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis. Vet. Dermatol. 2021;33:142-e40. doi: 10.1111/vde.13037.", "ArticleIdList": ["10.1111/vde.13037", "34747068"]}, {"Citation": "Collard W.T., Hummel B.D., Fielder A.F., King V.L., Boucher J.F., Mullins M.A., Malpas P.B., Stegemann M.R. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J. Vet. Pharmacol. Ther. 2014;37:279\u2013285. doi: 10.1111/jvp.12087.", "ArticleIdList": ["10.1111/jvp.12087", "24330031"]}, {"Citation": "Zoetisus.com APOQUEL\u00ae (Oclacitinib Tablet): Fast-Acting and Safe Itch Relief for Dogs.  [(accessed on 14 February 2022)].  Available online:  https://www.zoetisus.com/products/dogs/apoquel/assets/downloadable-resources/1413113_m03r_apl_infosheet_fda_labelupdate-_1__new2019.pdf."}, {"Citation": "FDA Approves Drug for Adults with Rare Form of Bone Marrow Disorder.  [(accessed on 17 April 2022)]; Available online:  https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder."}, {"Citation": "William A.D., Lee A.C.-H., Blanchard S., Poulsen A., Teo E.L., Nagaraj H., Tan E., Chen D., Williams M., Sun E.T., et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor. J. Med. Chem. 2011;54:4638\u20134658. doi: 10.1021/jm200326p.", "ArticleIdList": ["10.1021/jm200326p", "21604762"]}, {"Citation": "Singer J.W., Al-Fayoumi S., Ma H., Komrokji R.S., Mesa R., Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J. Exp. Pharmacol. 2016;8:11\u201319. doi: 10.2147/JEP.S110702.", "ArticleIdList": ["10.2147/JEP.S110702", "PMC4993559", "27574472"]}, {"Citation": "Klaeger S., Heinzlmeir S., Wilhelm M., Polzer H., Vick B., Koenig P.-A., Reinecke M., Ruprecht B., Petzoldt S., Meng C., et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368. doi: 10.1126/science.aan4368.", "ArticleIdList": ["10.1126/science.aan4368", "PMC6542668", "29191878"]}, {"Citation": "Mesa R.A., Vannucchi A.M., Mead A., Egyed M., Szoke A., Suvorov A., Jakucs J., Perkins A., Prasad R., Mayer J., et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet. Haematol. 2017;4:e225\u2013e236. doi: 10.1016/S2352-3026(17)30027-3.", "ArticleIdList": ["10.1016/S2352-3026(17)30027-3", "PMC8209752", "28336242"]}, {"Citation": "Mascarenhas J., Hoffman R., Talpaz M., Gerds A.T., Stein B., Gupta V., Szoke A., Drummond M., Pristupa A., Granston T., et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol. 2018;4:652\u2013659. doi: 10.1001/jamaoncol.2017.5818.", "ArticleIdList": ["10.1001/jamaoncol.2017.5818", "PMC5885169", "29522138"]}, {"Citation": "Hosseini M.M., Kurtz S.E., Abdelhamed S., Mahmood S., Davare M.A., Kaempf A., Elferich J., McDermott J.E., Liu T., Payne S.H., et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018;32:2374\u20132387. doi: 10.1038/s41375-018-0112-2.", "ArticleIdList": ["10.1038/s41375-018-0112-2", "PMC6558520", "29743719"]}, {"Citation": "Jeon J.Y., Zhao Q., Buelow D.R., Phelps M., Walker A.R., Mims A.S., Vasu S., Behbehani G., Blachly J., Blum W., et al. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investig. New Drugs. 2020;38:340\u2013349. doi: 10.1007/s10637-019-00786-4.", "ArticleIdList": ["10.1007/s10637-019-00786-4", "PMC6858927", "31102119"]}, {"Citation": "Jensen K.V., Cseh O., Aman A., Weiss S., Luchman H.A. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS ONE. 2017;12:e0189670. doi: 10.1371/journal.pone.0189670.", "ArticleIdList": ["10.1371/journal.pone.0189670", "PMC5734728", "29253028"]}, {"Citation": "Jayaraman R., Pasha M.K., Williams A., Goh K.C., Ethirajulu K. Metabolism and disposition of pacritinib (SB1518), an orally active Janus kinase 2 inhibitor in preclinical species and humans. Drug Metab. Lett. 2015;9:28\u201347. doi: 10.2174/1872312809666150119105250.", "ArticleIdList": ["10.2174/1872312809666150119105250", "25600203"]}, {"Citation": "Inoue T., Tanaka A., Nakai K., Sasaki H., Takahashi F., Shirakami S., Hatanaka K., Nakajima Y., Mukoyoshi K., Hamaguchi H., et al. Heterocyclic Janus Kinase 3 Inhibitors. WO2007077949A1. 2007 July 12;"}, {"Citation": "Ito M., Yamazaki S., Yamagami K., Kuno M., Morita Y., Okuma K., Nakamura K., Chida N., Inami M., Inoue T., et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J. Pharmacol. Sci. 2017;133:25\u201333. doi: 10.1016/j.jphs.2016.12.001.", "ArticleIdList": ["10.1016/j.jphs.2016.12.001", "28117214"]}, {"Citation": "Takeuchi T., Tanaka Y., Iwasaki M., Ishikura H., Saeki S., Kaneko Y. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann. Rheum. Dis. 2016;75:1057\u20131064. doi: 10.1136/annrheumdis-2015-208279.", "ArticleIdList": ["10.1136/annrheumdis-2015-208279", "PMC4893099", "26672064"]}, {"Citation": "Hamaguchi H., Amano Y., Moritomo A., Shirakami S., Nakajima Y., Nakai K., Nomura N., Ito M., Higashi Y., Inoue T. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg. Med. Chem. 2018;26:4971\u20134983. doi: 10.1016/j.bmc.2018.08.005.", "ArticleIdList": ["10.1016/j.bmc.2018.08.005", "30145050"]}, {"Citation": "Zhang J.-M., An J. Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 2007;45:27\u201337. doi: 10.1097/AIA.0b013e318034194e.", "ArticleIdList": ["10.1097/AIA.0b013e318034194e", "PMC2785020", "17426506"]}, {"Citation": "Takeuchi T., Tanaka Y., Tanaka S., Kawakami A., Song Y.-W., Chen Y.-H., Rokuda M., Izutsu H., Ushijima S., Kaneko Y. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Rheumatol. Ther. 2021;8:425\u2013442. doi: 10.1007/s40744-021-00280-5.", "ArticleIdList": ["10.1007/s40744-021-00280-5", "PMC7990977", "33656739"]}, {"Citation": "Genovese M.C., Greenwald M., Codding C., Zubrzycka-Sienkiewicz A., Kivitz A.J., Wang A., Shay K., Wang X., Garg J.P., Cardiel M.H. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69:932\u2013942. doi: 10.1002/art.40054.", "ArticleIdList": ["10.1002/art.40054", "28118538"]}, {"Citation": "Tanaka Y., Izutsu H. Peficitinib for the treatment of rheumatoid arthritis: An overview from clinical trials. Expert Opin. Pharmacother. 2020;21:1015\u20131025. doi: 10.1080/14656566.2020.1739649.", "ArticleIdList": ["10.1080/14656566.2020.1739649", "32345068"]}, {"Citation": "Takeuchi T., Tanaka Y., Tanaka S., Kawakami A., Song Y.-W., Chen Y.-H., Rokuda M., Izutsu H., Ushijima S., Kaneko Y., et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: Interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res. Ther. 2020;22:47. doi: 10.1186/s13075-020-2125-2.", "ArticleIdList": ["10.1186/s13075-020-2125-2", "PMC7068874", "32164762"]}, {"Citation": "Kaneko Y. Efficacy and safety of peficitinib in rheumatoid arthritis. Mod. Rheumatol. 2020;30:773\u2013778. doi: 10.1080/14397595.2020.1794103.", "ArticleIdList": ["10.1080/14397595.2020.1794103", "32643492"]}, {"Citation": "Oda K., Cao Y.J., Sawamoto T., Nakada N., Fisniku O., Nagasaka Y., Sohda K.-Y. Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45:887\u2013902. doi: 10.3109/00498254.2015.1026864.", "ArticleIdList": ["10.3109/00498254.2015.1026864", "25986538"]}, {"Citation": "Miyatake D., Shibata T., Toyoshima J., Kaneko Y., Oda K., Nishimura T., Katashima M., Sakaki M., Inoue K., Ito T., et al. Pharmacokinetics and safety of a single oral dose of peficitinib (ASP015K) in Japanese subjects with normal and impaired hepatic function. Clin. Pharmacol. Drug Dev. 2020;9:699\u2013708. doi: 10.1002/cpdd.751.", "ArticleIdList": ["10.1002/cpdd.751", "PMC7496893", "31833184"]}, {"Citation": "Yang W., Zhu G., Qin M., Li Z., Wang B., Yang J., Wang T. The effectiveness of ruxolitinib for acute/chronic graft-versus-host disease in children: A retrospective study. Drug Des. Devel. Ther. 2021;15:743\u2013752. doi: 10.2147/DDDT.S287218.", "ArticleIdList": ["10.2147/DDDT.S287218", "PMC7910527", "33654380"]}, {"Citation": "Rodgers D.J., Shepard S. Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors. US7598257B2. U.S. Patent. 2009 October 16;"}, {"Citation": "Haydl A.M., Xu K., Breit B. Regio- and enantioselective synthesis of N-substituted pyrazoles by rhodium-catalyzed asymmetric addition to allenes. Angew. Chemie Int. Ed. 2015;54:7149\u20137153. doi: 10.1002/anie.201501758.", "ArticleIdList": ["10.1002/anie.201501758", "25926026"]}, {"Citation": "Lin Q., Meloni D., Pan Y., Xia M., Rodgers J., Shepard S., Li M., Galya L., Metcalf B., Yue T.-Y., et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic Aza-Michael reaction. Org. Lett. 2009;11:1999\u20132002. doi: 10.1021/ol900350k.", "ArticleIdList": ["10.1021/ol900350k", "19385672"]}, {"Citation": "Zhou T., Georgeon S., Moser R., Moore D.J., Caflisch A., Hantschel O. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) Leukemia. 2014;28:404\u2013407. doi: 10.1038/leu.2013.205.", "ArticleIdList": ["10.1038/leu.2013.205", "23823659"]}, {"Citation": "Duan Y., Chen L., Chen Y., Fan X. c-Src binds to the cancer drug Ruxolitinib with an active conformation. PLoS ONE. 2014;9:e106225. doi: 10.1371/journal.pone.0106225.", "ArticleIdList": ["10.1371/journal.pone.0106225", "PMC4157781", "25197973"]}, {"Citation": "Quint\u00e1s-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., Caulder E., Wen X., Li Y., Waeltz P., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u20133117. doi: 10.1182/blood-2009-04-214957.", "ArticleIdList": ["10.1182/blood-2009-04-214957", "PMC3953826", "20130243"]}, {"Citation": "Arana Yi C., Tam C.S., Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 2015;11:719\u2013733. doi: 10.2217/fon.14.272.", "ArticleIdList": ["10.2217/fon.14.272", "PMC4920055", "25757677"]}, {"Citation": "Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., Catalano J.V., Deininger M., Miller C., Silver R.T., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012;366:799\u2013807. doi: 10.1056/NEJMoa1110557.", "ArticleIdList": ["10.1056/NEJMoa1110557", "PMC4822164", "22375971"]}, {"Citation": "Tavallai M., Booth L., Roberts J.L., Poklepovic A., Dent P. Rationally repurposing ruxolitinib (Jakafi (\u00ae)) as a solid tumor therapeutic. Front. Oncol. 2016;6:142. doi: 10.3389/fonc.2016.00142.", "ArticleIdList": ["10.3389/fonc.2016.00142", "PMC4904019", "27379204"]}, {"Citation": "Kim B.S., Howell M.D., Sun K., Papp K., Nasir A., Kuligowski M.E. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J. Allergy Clin. Immunol. 2020;145:572\u2013582. doi: 10.1016/j.jaci.2019.08.042.", "ArticleIdList": ["10.1016/j.jaci.2019.08.042", "31629805"]}, {"Citation": "Papp K., Szepietowski J.C., Kircik L., Toth D., Eichenfield L.F., Leung D.Y.M., Forman S.B., Venturanza M.E., Sun K., Kuligowski M.E., et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J. Am. Acad. Dermatol. 2021;85:863\u2013872. doi: 10.1016/j.jaad.2021.04.085.", "ArticleIdList": ["10.1016/j.jaad.2021.04.085", "33957195"]}, {"Citation": "Witkoff B., Logas C.M., Glick B.P., Del Rosso J.Q. JAK inhibitors in the treatment of atopic dermatitis. Dermatol. Rev. 2022;3:20\u201328. doi: 10.1002/der2.116.", "ArticleIdList": ["10.1002/der2.116"]}, {"Citation": "Sarmiento Maldonado M., Ram\u00edrez Villanueva P., Bert\u00edn Cortes-Monroy P., Jara Arias V., Soto Donoso K., Uribe Gonzalez P., Ocqueteau Tachini M., Perez-Sim\u00f3n J.A. Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. Exp. Hematol. Oncol. 2017;6:32. doi: 10.1186/s40164-017-0092-3.", "ArticleIdList": ["10.1186/s40164-017-0092-3", "PMC5712115", "29214116"]}, {"Citation": "Przepiorka D., Luo L., Subramaniam S., Qiu J., Gudi R., Cunningham L.C., Nie L., Leong R., Ma L., Sheth C., et al. FDA approval summary: Ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25:e328\u2013e334. doi: 10.1634/theoncologist.2019-0627.", "ArticleIdList": ["10.1634/theoncologist.2019-0627", "PMC7011641", "32043777"]}, {"Citation": "Shilling A.D., Nedza F.M., Emm T., Diamond S., McKeever E., Punwani N., Williams W., Arvanitis A., Galya L.G., Li M., et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab. Dispos. 2010;38:2023\u20132031. doi: 10.1124/dmd.110.033787.", "ArticleIdList": ["10.1124/dmd.110.033787", "20699411"]}, {"Citation": "Shi J.G., Chen X., Emm T., Scherle P.A., McGee R.F., Lo Y., Landman R.R., McKeever E.G.J., Punwani N.G., Williams W.V., et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J. Clin. Pharmacol. 2012;52:809\u2013818. doi: 10.1177/0091270011405663.", "ArticleIdList": ["10.1177/0091270011405663", "21602517"]}, {"Citation": "Aschenbrenner D.S. Tofacitinib trial prompts FDA review of adverse effects. Am. J. Nurs. 2019;119:25. doi: 10.1097/01.NAJ.0000559803.24361.5e.", "ArticleIdList": ["10.1097/01.NAJ.0000559803.24361.5e", "31135426"]}, {"Citation": "Berbert Ferreira S., Berbert Ferreira R., Neves Neto A.C., Assef S.M.C., Scheinberg M. Topical tofacitinib: A Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient. Case Rep. Dermatol. 2021;13:190\u2013194. doi: 10.1159/000513938.", "ArticleIdList": ["10.1159/000513938", "PMC8488419", "34703426"]}, {"Citation": "Kostik M.M., Raupov R.K., Suspitsin E.N., Isupova E.A., Gaidar E.V., Gabrusskaya T.V., Kaneva M.A., Snegireva L.S., Likhacheva T.S., Miulkidzhan R.S., et al. The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: Single centre experience. Front. Pediatr. 2022;10:820586. doi: 10.3389/fped.2022.820586.", "ArticleIdList": ["10.3389/fped.2022.820586", "PMC8861449", "35211430"]}, {"Citation": "Mohanakrishnan R., Beier S., Deodhar A. Tofacitinib for the treatment of active ankylosing spondylitis in adults. Expert Rev. Clin. Immunol. 2022;18:273\u2013280. doi: 10.1080/1744666X.2022.2038134.", "ArticleIdList": ["10.1080/1744666X.2022.2038134", "35152808"]}, {"Citation": "Blumenkopf T.A., Flanagan M.E., Munchhof M.J. Pyrrolo[2,3-d]pyrimidine Compounds. US6956041B2. U.S. Patent. 2005 October 18;"}, {"Citation": "Cai W., Colony J.L., Frost H., Hudspeth J.P., Kendall P.M., Krishnan A.M., Makowski T., Mazur D.J., Phillips J., Ripin D.H.B., et al. Investigation of practical routes for the kilogram-scale production of cis-3-methylamino-4-methylpiperidines. Org. Process Res. Dev. 2005;9:51\u201356. doi: 10.1021/op049808k.", "ArticleIdList": ["10.1021/op049808k"]}, {"Citation": "Williams N.K., Bamert R.S., Patel O., Wang C., Walden P.M., Wilks A.F., Fantino E., Rossjohn J., Lucet I.S. Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 2009;387:219\u2013232. doi: 10.1016/j.jmb.2009.01.041.", "ArticleIdList": ["10.1016/j.jmb.2009.01.041", "19361440"]}, {"Citation": "Chrencik J.E., Patny A., Leung I.K., Korniski B., Emmons T.L., Hall T., Weinberg R.A., Gormley J.A., Williams J.M., Day J.E., et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 2010;400:413\u2013433. doi: 10.1016/j.jmb.2010.05.020.", "ArticleIdList": ["10.1016/j.jmb.2010.05.020", "20478313"]}, {"Citation": "Chamberlain P., Delker S., Pagarigan B., Mahmoudi A., Jackson P., Abbasian M., Muir J., Raheja N., Cathers B. Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes. PLoS ONE. 2014;9:e103638. doi: 10.1371/journal.pone.0103638.", "ArticleIdList": ["10.1371/journal.pone.0103638", "PMC4128815", "25111382"]}, {"Citation": "Fleischmann R., Kremer J., Cush J., Schulze-Koops H., Connell C.A., Bradley J.D., Gruben D., Wallenstein G.V., Zwillich S.H., Kanik K.S. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012;367:495\u2013507. doi: 10.1056/NEJMoa1109071.", "ArticleIdList": ["10.1056/NEJMoa1109071", "22873530"]}, {"Citation": "Van Vollenhoven R.F., Fleischmann R., Cohen S., Lee E.B., Garc\u00eda Meijide J.A., Wagner S., Forejtova S., Zwillich S.H., Gruben D., Koncz T., et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. N. Engl. J. Med. 2012;367:508\u2013519. doi: 10.1056/NEJMoa1112072.", "ArticleIdList": ["10.1056/NEJMoa1112072", "22873531"]}, {"Citation": "Van der Heijde D., Tanaka Y., Fleischmann R., Keystone E., Kremer J., Zerbini C., Cardiel M.H., Cohen S., Nash P., Song Y.-W., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four\u2013month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u2013570. doi: 10.1002/art.37816.", "ArticleIdList": ["10.1002/art.37816", "23348607"]}, {"Citation": "Gladman D., Rigby W., Azevedo V.F., Behrens F., Blanco R., Kaszuba A., Kudlacz E., Wang C., Menon S., Hendrikx T., et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 2017;377:1525\u20131536. doi: 10.1056/NEJMoa1615977.", "ArticleIdList": ["10.1056/NEJMoa1615977", "29045207"]}, {"Citation": "Mease P., Hall S., FitzGerald O., van der Heijde D., Merola J.F., Avila-Zapata F., Cie\u015blak D., Graham D., Wang C., Menon S., et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N. Engl. J. Med. 2017;377:1537\u20131550. doi: 10.1056/NEJMoa1615975.", "ArticleIdList": ["10.1056/NEJMoa1615975", "29045212"]}, {"Citation": "Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 2012;367:616\u2013624. doi: 10.1056/NEJMoa1112168.", "ArticleIdList": ["10.1056/NEJMoa1112168", "22894574"]}, {"Citation": "Huang Z., Lee P.Y., Yao X., Zheng S., Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019;143:e20182845. doi: 10.1542/peds.2018-2845.", "ArticleIdList": ["10.1542/peds.2018-2845", "30948682"]}, {"Citation": "Dowty M.E., Lin J., Ryder T.F., Wang W., Walker G.S., Vaz A., Chan G.L., Krishnaswami S., Prakash C. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab. Dispos. 2014;42:759\u2013773. doi: 10.1124/dmd.113.054940.", "ArticleIdList": ["10.1124/dmd.113.054940", "24464803"]}, {"Citation": "Guo X., Li W., Li Q., Chen Y., Zhao G., Peng Y., Zheng J. Tofacitinib is a mechanism-based inactivator of cytochrome P450 3A4. Chem. Res. Toxicol. 2019;32:1791\u20131800. doi: 10.1021/acs.chemrestox.9b00141.", "ArticleIdList": ["10.1021/acs.chemrestox.9b00141", "31414593"]}, {"Citation": "Muensterman E., Engelhardt B., Gopalakrishnan S., Anderson J.K., Mohamed M.-E.F. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients\u2014Analyses of phase III clinical trials. Clin. Transl. Sci. 2022;15:267\u2013278. doi: 10.1111/cts.13146.", "ArticleIdList": ["10.1111/cts.13146", "PMC8742648", "34464029"]}, {"Citation": "AbbVie U.S. FDA Approves RINVOQ\u00ae (Upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis.  [(accessed on 20 April 2022)].  Available online:  https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm#:~:text=14%2C2022%2FPRNewswire%2F."}, {"Citation": "AbbVie RINVOQ\u00ae (Upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis.  [(accessed on 19 April 2022)].  Available online:  https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-fda-approval-for-treatment-adults-with-moderately-to-severely-active-ulcerative-colitis.htm."}, {"Citation": "Allian A., Jayanth J., Mohamed M.-E., Mulhern M., Nordstroem L.F., Othman A., Rozema M., Bhagavatula L., Marroum P.J., Mayer P.T. Processes for the Preparation of (3S,4R)-3-Ethyl-4-(3H-Imidazo[1,2-a]Pyrrolo[2,3-e]-Pyrazin-8-yl)-N-(2,2,2-Trifluoroethyl)Pyrrolidine-1-Carboxamide and Solid State Forms Thereof. WO2017066775A1. 2017 April 20;"}, {"Citation": "Parmentier J.M., Voss J., Graff C., Schwartz A., Argiriadi M., Friedman M., Camp H.S., Padley R.J., George J.S., Hyland D., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) BMC Rheumatol. 2018;2:23. doi: 10.1186/s41927-018-0031-x.", "ArticleIdList": ["10.1186/s41927-018-0031-x", "PMC6390583", "30886973"]}, {"Citation": "Padda I.S., Bhatt R., Parmar M. Upadacitinib. StatPearls Publishing; Treasure Island, FL, USA: 2021."}, {"Citation": "Strand V., Mease P.J., Soriano E.R., Kishimoto M., Salvarani C., Saffore C.D., Zueger P., McDearmon-Blondell E., Kato K., Gladman D.D. Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: Results from SELECT-PsA 1. Rheumatol. Ther. 2021;8:1789\u20131808. doi: 10.1007/s40744-021-00379-9.", "ArticleIdList": ["10.1007/s40744-021-00379-9", "PMC8572257", "34636026"]}, {"Citation": "Serhal L., Edwards C.J. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 2019;15:13\u201325. doi: 10.1080/1744666X.2019.1544892.", "ArticleIdList": ["10.1080/1744666X.2019.1544892", "30394138"]}, {"Citation": "Bergman M., Tundia N., Yang M., Orvis E., Clewell J., Bensimon A. Economic benefit from improvements in quality of life with upadacitinib: Comparisons with tofacitinib and methotrexate in patients with rheumatoid arthritis. Adv. Ther. 2021;38:5649\u20135661. doi: 10.1007/s12325-021-01930-4.", "ArticleIdList": ["10.1007/s12325-021-01930-4", "PMC8572211", "34636000"]}, {"Citation": "Smolen J.S., Pangan A.L., Emery P., Rigby W., Tanaka Y., Vargas J.I., Zhang Y., Damjanov N., Friedman A., Othman A.A., et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): A randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u20132311. doi: 10.1016/S0140-6736(19)30419-2.", "ArticleIdList": ["10.1016/S0140-6736(19)30419-2", "31130260"]}, {"Citation": "McInnes I.B., Anderson J.K., Magrey M., Merola J.F., Liu Y., Kishimoto M., Jeka S., Pacheco-Tena C., Wang X., Chen L., et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N. Engl. J. Med. 2021;384:1227\u20131239. doi: 10.1056/NEJMoa2022516.", "ArticleIdList": ["10.1056/NEJMoa2022516", "33789011"]}, {"Citation": "Burmester G.R., Winthrop K., Blanco R., Nash P., Goupille P., Azevedo V.F., Salvarani C., Rubbert-Roth A., Lesser E., Lippe R., et al. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: An integrated analysis of two pivotal phase 3 trials. Rheumatol. Ther. 2021;9:521\u2013539. doi: 10.1007/s40744-021-00410-z.", "ArticleIdList": ["10.1007/s40744-021-00410-z", "PMC8717827", "34970731"]}, {"Citation": "Funk P.J., Perche P.O., Singh R., Kelly K.A., Feldman S.R. Comparing available JAK inhibitors for treating patients with psoriasis. Expert Rev. Clin. Immunol. 2022;18:281\u2013294. doi: 10.1080/1744666X.2022.2039121.", "ArticleIdList": ["10.1080/1744666X.2022.2039121", "35129030"]}, {"Citation": "Blauvelt A., Teixeira H.D., Simpson E.L., Costanzo A., De Bruin-Weller M., Barbarot S., Prajapati V.H., Lio P., Hu X., Wu T., et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2021;157:1047\u20131055. doi: 10.1001/jamadermatol.2021.3023.", "ArticleIdList": ["10.1001/jamadermatol.2021.3023", "PMC8340015", "34347860"]}, {"Citation": "Mohamed M.-E.F., Camp H.S., Jiang P., Padley R.J., Asatryan A., Othman A.A. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin. Pharmacokinet. 2016;55:1547\u20131558. doi: 10.1007/s40262-016-0419-y.", "ArticleIdList": ["10.1007/s40262-016-0419-y", "27272171"]}, {"Citation": "Mohamed M.-E.F., Jungerwirth S., Asatryan A., Jiang P., Othman A.A. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br. J. Clin. Pharmacol. 2017;83:2242\u20132248. doi: 10.1111/bcp.13329.", "ArticleIdList": ["10.1111/bcp.13329", "PMC5595971", "28503781"]}, {"Citation": "Mohamed M.-E.F., Kl\u00fcnder B., Othman A.A. Clinical pharmacokinetics of upadacitinib: Review of data relevant to the rheumatoid arthritis indication. Clin. Pharmacokinet. 2020;59:531\u2013544. doi: 10.1007/s40262-019-00855-0.", "ArticleIdList": ["10.1007/s40262-019-00855-0", "PMC7217812", "31867699"]}, {"Citation": "Vainchenker W., Favale F. Myelofibrosis, JAK2 inhibitors and erythropoiesis. Leukemia. 2013;27:1219\u20131223. doi: 10.1038/leu.2013.72.", "ArticleIdList": ["10.1038/leu.2013.72", "23739260"]}, {"Citation": "Wood H., Chandler A., Nezamololama N., Papp K., Gooderham M.J. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int. J. Dermatol. 2021 doi: 10.1111/ijd.15853.", "ArticleIdList": ["10.1111/ijd.15853", "34423443"]}, {"Citation": "Minshawi F., Lanvermann S., McKenzie E., Jeffery R., Couper K., Papoutsopoulou S., Roers A., Muller W. The generation of an engineered interleukin-10 protein with improved stability and biological function. Front. Immunol. 2020;11:1794. doi: 10.3389/fimmu.2020.01794.", "ArticleIdList": ["10.3389/fimmu.2020.01794", "PMC7431522", "32849644"]}, {"Citation": "Almoallim H.M., Alharbi L.A. Rheumatoid arthritis in Saudi Arabia. Saudi Med. J. 2014;35:1442\u20131454.", "ArticleIdList": ["PMC4362178", "25491208"]}, {"Citation": "Hussain W., Janoudi N., Noorwali A., Omran N., Baamer M., Assiry E.H., Alrayes H., Alosaimi H., Ibrahim A., Gohary S., et al. Effect of adalimumab on work ability assessed in rheumatoid arthritis disease patients in Saudi Arabia (AWARDS) Open Rheumatol. J. 2015;9:46\u201350. doi: 10.2174/1874312901409010046.", "ArticleIdList": ["10.2174/1874312901409010046", "PMC4541458", "26312105"]}, {"Citation": "O\u2019Shea J.J., Gadina M. Selective Janus kinase inhibitors come of age. Nat. Rev. Rheumatol. 2019;15:74\u201375. doi: 10.1038/s41584-018-0155-9.", "ArticleIdList": ["10.1038/s41584-018-0155-9", "30622297"]}, {"Citation": "Pardanani A., Lasho T., Smith G., Burns C.J., Fantino E., Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23:1441\u20131445. doi: 10.1038/leu.2009.50.", "ArticleIdList": ["10.1038/leu.2009.50", "19295546"]}, {"Citation": "Sideris N., Vakirlis E., Tsentemeidou A., Kourouklidou A., Ioannides D., Sotiriou E. Under development JAK inhibitors for dermatologic diseases. Mediterr. J. Rheumatol. 2020;31:137\u2013144. doi: 10.31138/mjr.31.1.137.", "ArticleIdList": ["10.31138/mjr.31.1.137", "PMC7361191", "32676572"]}, {"Citation": "Ma J., Xing W., Coffey G., Dresser K., Lu K., Guo A., Raca G., Pandey A., Conley P., Yu H., et al. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget. 2015;6:43881\u201343896. doi: 10.18632/oncotarget.6316.", "ArticleIdList": ["10.18632/oncotarget.6316", "PMC4791274", "26575169"]}, {"Citation": "Nogueira M., Puig L., Torres T. JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors. Drugs. 2020;80:341\u2013352. doi: 10.1007/s40265-020-01261-8.", "ArticleIdList": ["10.1007/s40265-020-01261-8", "32020553"]}, {"Citation": "Schroeder M.A., Khoury H.J., Jagasia M., Ali H., Schiller G.J., Staser K., Choi J., Gehrs L., Arbushites M.C., Yan Y., et al. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020;4:1656\u20131669. doi: 10.1182/bloodadvances.2019001043.", "ArticleIdList": ["10.1182/bloodadvances.2019001043", "PMC7189299", "32324888"]}, {"Citation": "Verstovsek S., Mesa R.A., Salama M.E., Li L., Pitou C., Nunes F.P., Price G.L., Giles J.L., D\u2019Souza D.N., Walgren R.A., et al. A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk. Res. 2017;61:89\u201395. doi: 10.1016/j.leukres.2017.08.010.", "ArticleIdList": ["10.1016/j.leukres.2017.08.010", "PMC8207330", "28934680"]}, {"Citation": "Verstovsek S., Odenike O., Singer J.W., Granston T., Al-Fayoumi S., Deeg H.J. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J. Hematol. Oncol. 2016;9:137. doi: 10.1186/s13045-016-0367-x.", "ArticleIdList": ["10.1186/s13045-016-0367-x", "PMC5146859", "27931243"]}, {"Citation": "Genovese M.C., van Vollenhoven R.F., Pacheco-Tena C., Zhang Y., Kinnman N. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46\u201355. doi: 10.1002/art.39473.", "ArticleIdList": ["10.1002/art.39473", "26473751"]}, {"Citation": "Tan L., Akahane K., McNally R., Reyskens K.M.S.E., Ficarro S.B., Liu S., Herter-Sprie G.S., Koyama S., Pattison M.J., Labella K., et al. Development of selective covalent Janus kinase 3 inhibitors. J. Med. Chem. 2015;58:6589\u20136606. doi: 10.1021/acs.jmedchem.5b00710.", "ArticleIdList": ["10.1021/acs.jmedchem.5b00710", "PMC4777322", "26258521"]}, {"Citation": "Tanaka Y., Luo Y., O\u2019Shea J.J., Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat. Rev. Rheumatol. 2022;18:133\u2013145. doi: 10.1038/s41584-021-00726-8.", "ArticleIdList": ["10.1038/s41584-021-00726-8", "PMC8730299", "34987201"]}, {"Citation": "Jin W., Stokes J.M., Eastman R.T., Itkin Z., Zakharov A.V., Collins J.J., Jaakkola T.S., Barzilay R. Deep learning identifies synergistic drug combinations for treating COVID-19. Proc. Natl. Acad. Sci. USA. 2021;118:e2105070118. doi: 10.1073/pnas.2105070118.", "ArticleIdList": ["10.1073/pnas.2105070118", "PMC8488647", "34526388"]}, {"Citation": "Sayed Ahmed H.A., Merrell E., Ismail M., Joudeh A.I., Riley J.B., Shawkat A., Habeb H., Darling E., Goweda R.A., Shehata M.H., et al. Rationales and uncertainties for aspirin use in COVID-19: A narrative review. Fam. Med. Community Health. 2021;9:e000741. doi: 10.1136/fmch-2020-000741.", "ArticleIdList": ["10.1136/fmch-2020-000741", "PMC8061559", "33879541"]}, {"Citation": "Marconi V.C., Ramanan A.V., de Bono S., Kartman C.E., Krishnan V., Liao R., Piruzeli M.L.B., Goldman J.D., Alatorre-Alexander J., de Cassia Pellegrini R., et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9:1407\u20131418. doi: 10.1016/S2213-2600(21)00331-3.", "ArticleIdList": ["10.1016/S2213-2600(21)00331-3", "PMC8409066", "34480861"]}, {"Citation": "Kmietowicz Z. COVID-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ. 2022;376:o97. doi: 10.1136/bmj.o97.", "ArticleIdList": ["10.1136/bmj.o97", "35027362"]}, {"Citation": "Guimar\u00e3es P.O., Quirk D., Furtado R.H., Maia L.N., Saraiva J.F., Antunes M.O., Kalil Filho R., Junior V.M., Soeiro A.M., Tognon A.P., et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 2021;385:406\u2013415. doi: 10.1056/NEJMoa2101643.", "ArticleIdList": ["10.1056/NEJMoa2101643", "PMC8220898", "34133856"]}, {"Citation": "Seror R., Camus M., Salmon J.-H., Roux C., Dernis E., Basch A., Germain V., Leske C., Brousseau S., Truchetet M.-E., et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet. Rheumatol. 2022;4:e8\u2013e11. doi: 10.1016/S2665-9913(21)00314-3.", "ArticleIdList": ["10.1016/S2665-9913(21)00314-3", "PMC8494471", "34642669"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "1"}, {"Year": "2022", "Month": "4", "Day": "22"}, {"Year": "2022", "Month": "4", "Day": "28"}, {"Year": "2022", "Month": "5", "Day": "28", "Hour": "1", "Minute": "39"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "5", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["35631587", "PMC9146299", "10.3390/pharmaceutics14051001", "pharmaceutics14051001"]}}], "PubmedBookArticle": []}